Replimune's SWOT analysis: oncolytic immunotherapy stock faces pivotal year
Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment, ...
Strong Buy Rating for Replimune Group Due to Promising RP1 + Opdivo Results and Favorable FDA Review
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price ...
Replimune's BLA For RP1-Nivolumab Combo Gets FDA Approval For Advanced Melanoma, Stock Surges
(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...
Managed Healthcare Executive9h
BLA Accepted for Melanoma Combination Therapy, RP1 and Nivolumab
The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...
Replimune stock soars on FDA priority review for melanoma treatment
Shares of Replimune Group, Inc. (NASDAQ: NASDAQ: REPL) surged 17% following the announcement that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ...
The Pharma Letter16h
FDA accepts Replimune’s melanoma candidate for priority review
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...
Replimune's SWOT analysis: biotech firm's stock poised for growth in oncology
Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment with a current market capitalization of $803 million, has been making ...
Replimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma Therapy
Replimune Group ( REPL, Financials) shares surged 17% to $11.85 as of 10:18 a.m. ET Tuesday after the U.S. Food and Drug Administration granted Priority Review for its Biologics License Application ...
Targeted Oncology1d
FDA Accepts BLA for RP1 With Nivolumab in Advanced Melanoma
The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...
Investing6d
Replimune's SWOT analysis: biotech firm's stock poised for growth in oncology
Recent developments have placed Replimune on a promising trajectory. The company is preparing for a crucial milestone: the submission of a Biologics License Application (BLA) for RP1 in advanced ...
Investing6d
Replimune's SWOT analysis: biotech firm's stock poised for growth in oncology
The company's primary focus is on developing novel treatments for various types of cancer, with its lead product candidate, RP1, at the forefront of its efforts. Recent developments have placed ...
Nasdaq14d
Replimune announces RP2 development program advances
Replimune (REPL) Group announced that the first ... “On the heels of our BLA submission for RP1 and designation as breakthrough therapy, we are pleased that the first patients have been enrolled ...